ZIOPHARM Oncology to Present Updated Clinical Results of Gene Therapy Candidate Ad-RTS-hIL-12 + Veledimex in Recurrent Gliobl...
April 20 2017 - 4:05PM
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company
focused on new immunotherapies, today announced that it will
present updated results from its Phase 1, multicenter,
dose-escalation study of Ad-RTS-hIL-12 + orally administered
veledimex in patients with recurrent or progressive glioblastoma at
the 2017 American Society of Clinical Oncology (ASCO) Annual
Meeting to be held June 2-6 in Chicago. Ad-RTS-hIL-12 + veledimex
is a novel, viral gene therapy candidate for the controlled
expression of interleukin-12 (IL-12), a pro-inflammatory cytokine
critical for stimulating anti-cancer immune responses.
Details for the poster presentation at
ASCO 2017:
Title: Expanded phase I study
of intratumoral Ad-RTS-hIL-12 plus oral veledimex: Tolerability and
survival in recurrent glioblastomaAbstract Number:
2044Session: Central Nervous System
TumorsDate and Time: Monday, June 5, 2017, 1:15 –
4:45 p.m. CT
About ZIOPHARM Oncology,
Inc.:
ZIOPHARM Oncology is a Boston,
Massachusetts-based biotechnology company employing novel gene
expression, control and cell technologies to deliver safe,
effective and scalable cell- and viral-based therapies for the
treatment of cancer and graft-versus-host-disease. The Company's
immuno-oncology programs, in collaboration with Intrexon
Corporation (NYSE:XON) and the MD Anderson Cancer Center, include
chimeric antigen receptor T cell (CAR-T) and other adoptive
cell-based approaches that use non-viral gene transfer methods for
broad scalability. The Company is advancing programs in multiple
stages of development together with Intrexon Corporation's
RheoSwitch Therapeutic System® technology, a switch to turn on and
off, and precisely modulate, gene expression in order to improve
therapeutic index. The Company's pipeline includes a number of
cell-based therapeutics in both clinical and preclinical testing
which are focused on hematologic and solid tumor malignancies.
Forward-Looking Safe-Harbor
Statement:
This press release contains certain
forward-looking information about ZIOPHARM Oncology, Inc. that is
intended to be covered by the safe harbor for "forward-looking
statements" provided by the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts, and in some cases can be identified
by terms such as "may," "will," "could," "expects," "plans,"
"anticipates," and "believes." All of such statements are subject
to certain risks and uncertainties, many of which are difficult to
predict and generally beyond the control of the Company, that could
cause actual results to differ materially from those expressed in,
or implied by, the forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk factors
contained in our periodic and interim reports filed with the
Securities and Exchange Commission, including but not limited to,
our Annual Report on Form 10-K for the fiscal year ended December
31, 2016. Readers are cautioned not to place undue reliance on
these forward-looking statements that speak only as of the date
hereof, and we do not undertake any obligation to revise and
disseminate forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence
of or non-occurrence of any events.
TrademarksRheoSwitch
Therapeutic System® and RTS® are registered trademarks of Intrexon
Corporation.
Contact:
Amy Trevvett
Vice President, Corporate Communications and Investor Relations
617-502-1881
atrevvett@ziopharm.com
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
Intrexon (NASDAQ:XON)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intrexon (NASDAQ:XON)
Historical Stock Chart
From Apr 2023 to Apr 2024